Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .BOSTON--(BUSINESS WIRE)--Nov. 27, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET.
波士顿--(美国商业资讯)--2024年11月27日--致力于发现和提供下一代精准癌症药物的临床阶段生物技术公司Tango Therapeutics, Inc.（纳斯达克股票代码：TNGX）今天宣布，Tango Therapeutics研发总裁亚当·克里斯塔尔万博士定于12月5日星期四出席派珀·桑德勒第36届年度医疗保健会议。2024 年美国东部时间下午 1:30
A live webcast of the presentation will be available under the "Events & Presentations" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
活动当天，将在公司网站 “投资者” 页面的 “活动和演讲” 选项卡下提供演示的网络直播。网络直播的重播将在演示结束后的90天内在公司网站上存档。
About Tango Therapeutics
关于探戈疗法
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit .
Tango Therapeutics是一家处于临床阶段的生物技术公司，致力于发现新的药物靶标并提供用于治疗癌症的下一代精准医学。Tango采用以患者为起点和终点的方法，利用合成杀伤力的遗传原理来发现和开发针对癌症关键靶标的疗法。欲了解更多信息，请访问。
View source version on businesswire.com:
在 businesswire.com 上查看源版本：
Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media Contact:
Amanda Brown Galgay
SVP, Corporate Communications, Tango Therapeutics
media@tangotx.com
投资者联系方式：
山姆·马丁/安德鲁·瓦利斯
Argot 合作伙伴
tango@argotpartners.com
媒体联系人：
阿曼达·布朗·加尔盖
Tango Therapeutics 企业传播高级副总裁
media@tangotx.com
Source: Tango Therapeutics, Inc.
资料来源：Tango Therapeutics, Inc.
